SCHEMBL1137602

SCHEMBL1137602

CCOC(=O)/C=C/c1cn(C)c2cccc(Oc3ccc(F)cc3Cl)c12

nearest known ligand 0.63

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ PTGER3 P43115 20/20 0.63
▸ PTGFR P43088 8/20 0.55
▸ PTGER2 P43116 5/20 0.55
▸ PTGER4 P35408 4/20 0.55
▸ PTGER1 P34995 3/20 0.55
▸ PTGIR P43119 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1137605 1.00 PTGER3 (0.63) PTGER3PTGFRPTGER2PTGER4PTGER1
SCHEMBL1137599 0.91 PTGER3 (0.61) PTGER3PTGFRPTGER2PTGER4PTGER1
SCHEMBL1137604 0.91 PTGER3 (0.61) PTGER3PTGFRPTGER2PTGER4PTGER1
SCHEMBL1137663 0.90 PTGER3 (0.63) PTGER3PTGFRPTGER2PTGER4PTGER1
SCHEMBL1137667 0.90 PTGER3 (0.63) PTGER3PTGFRPTGER2PTGER4PTGER1
SCHEMBL1138066 0.88 PTGER3 (0.64) PTGER3PTGFRPTGER2PTGER4PTGER1
SCHEMBL1138069 0.88 PTGER3 (0.64) PTGER3PTGFRPTGER2PTGER4PTGER1
SCHEMBL1137616 0.87 PTGER3 (0.68) PTGER3PTGFRPTGER2PTGER4PTGER1
SCHEMBL1137610 0.87 PTGER3 (0.68) PTGER3PTGFRPTGER2PTGER4PTGER1
SCHEMBL1137712 0.86 PTGER3 (0.48) PTGER3PTGFRPTGER2PTGER4PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1812388-B1 SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE DECODE GENETICS EHF (IS) 2011-02-23 — — EP disclosed
US-7714017-B2 for prostaglandin-mediated disorders; (E)-3-[1-(2,4-Dichloro-benzyl)-3,3-bis-hydroxymethyl-2-oxo-2,3-dihydro-1H-indol-7-yl]-acrylic acid DECODE GENETICS, EHF (IS) 2010-05-11 — — US disclosed
US-20090291948-A1 SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE DECODE GENETICS EHF (IS) 2009-11-26 — — US disclosed
US-7598397-B2 Sulfonamide peri-substituted bicyclics for occlusive artery disease DECODE GENETICS EHF (IS) 2009-10-06 — — US disclosed
EP-1814881-A2 CARBOXYLIC ACID PERI - SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE Decode Genetics, Inc. (US) 2007-08-08 — — EP disclosed
EP-1812388-A1 SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE Decode Genetics (US) 2007-08-01 — — EP disclosed
US-20060142355-A1 Carboxylic acid peri-substituted bicyclics for occlusive artery disease DECODE CHEMISTRY, INC. (US) 2006-06-29 — — US disclosed
WO-2006044000-A1 SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE DECODE GENETICS (US) 2006-04-27 — — WO disclosed
WO-2006044415-A2 CARBOXYLIC ACID PERI - SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE DECODE GENETICS, INC. (US) 2006-04-27 — — WO disclosed
US-20060079520-A1 Sulfonamide peri-substituted bicyclics for occlusive artery disease SAGA INVESTMENTS LLC 2006-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079520-A1 Sulfonamide peri-substituted bicyclics for occlusive artery disease PTGIS, PTGIR, PTGS2 PTGER3 19/4885PTGFR 11/4885PTGER2 18/4885
US-20090291948-A1 SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE PTGIS, PTGIR, PTGS2 PTGER3 19/4885PTGFR 11/4885PTGER2 18/4885
US-20060142355-A1 Carboxylic acid peri-substituted bicyclics for occlusive artery disease PTGIS, PTGIR, PTGDR PTGER3 19/4885PTGFR 4/4885PTGER2 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback